Yuhan to become largest shareholder in Theragen Etex

Published: 2012-12-04 06:57:00

Updated: 2012-12-04 06:57:00

Theragen Etex, a Korean research and development company looking at biologics and small molecules, said Monday that Yuhan Corp. will become the largest shareholder as it holds a 9.18 percent stake.

Last August, Theragen and Yuhan signed an agreement to commercialize Theragen’s "Hellogenom," wh...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK